Racial Difference in Human Platelet PAR4 Reactivity Reflects Expression of PCTP and miR-376c
View/ Open
Author
Edelstein, Leonard C.
Simon, Lukas M.
Montoya, Raúl Teruel
Holinstat, Michael
Chen, Edward S.
Bergeron, Angela
Kong, Xianguo
Nagalla, Srikanth
Mohandas, Narla
Dong, Jing-fei
Shaw, Chad
Bray, Paul F.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/nm.3385Metadata
Show full item recordCitation
Edelstein, L. C., L. M. Simon, R. T. Montoya, M. Holinstat, E. S. Chen, A. Bergeron, X. Kong, et al. 2013. “Racial Difference in Human Platelet PAR4 Reactivity Reflects Expression of PCTP and miR-376c.” Nature medicine 19 (12): 10.1038/nm.3385. doi:10.1038/nm.3385. http://dx.doi.org/10.1038/nm.3385.Abstract
Racial differences in the pathophysiology of atherothrombosis are poorly understood. We explored the function and transcriptome of platelets in healthy black (n = 70) and white (n = 84) subjects. PAR4 thrombin receptor induced platelet aggregation and calcium mobilization were significantly greater in black subjects. Numerous differentially expressed (DE) RNAs were associated with both race and PAR4 reactivity, including phosphatidylcholine transfer protein (PCTP), and platelets from blacks expressed higher levels of PC-TP protein. PC-TP inhibition or depletion blocked activation of platelets or megakaryocytic cell lines through PAR4 but not PAR1. MiR-376c levels were DE by race and PAR4 reactivity, and were inversely correlated with PCTP mRNA levels, PC-TP protein levels and PAR4 reactivity. MiR-376c regulated expression of PC-TP in human megakaryocytes. A disproportionately high number of miRNAs DE by race and PAR4 reactivity, including miR-376c, are encoded in the DLK1-DIO3 locus, and were lower in platelets from blacks. These results support PC-TP as a regulator of the racial difference in PAR4-mediated platelet activation, indicate a genomic contribution to platelet function that differs by race, and emphasize a need to consider race effects when developing anti-thrombotic drugs.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855898/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406670
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)